期刊
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
卷 81, 期 5, 页码 895-899出版社
AMER SOC TROP MED & HYGIENE
DOI: 10.4269/ajtmh.2009.09-0189
关键词
-
资金
- World Health Organization
- Pacific Leprosy Trust (New Zealand)
- Sasakawa Memorial Health Foundation (Japan)
From 1987 to 1994, we enrolled 500 subjects completing 2-year WHO multiple drug therapy (MDT) for multibacillary leprosy in a prospective relapse study. Relapse was defined as new skin lesions and an increase in the bacterial index (BI) >= 2+ (>= 100x) at any single slit-skin smear site. At the study end in 2006, follow-up was 6,401 subject-years, a mean of 12.8 years/subject. We observed 23 relapses, 6-16 years after MDT (mean, 10.5 years; 95% confidence interval [CI], 9.2-11.8), peaking in Years 11-12 (> 1%/year). The cumulative risk was 6.6% (95% Cl, 5.0-8.2%). In a subset of 181 subjects with pre-MDT average BI >= 4+, 11 relapses occurred (cumulative risk, 10.1%). In mouse footpad assays, Mycobacterium leprae from relapsed subjects were rifampin and clofazimine sensitive. Taken together, the data suggest relapses are related to activation of dormant organisms (persisters) not killed by MDT rather than new infection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据